RE:RE:RE:RE:Dr. Lilge OSA Webinar - Aug. 18 The Clinical Protocol will certainly be interesting given the array of potential adjuvants already announced by the Company (cannabinoid,vaccine,CLT). Two extracts from the last Quarterly;
‘Due to the limitations of using laser light to activate Rutherrin® in deep oncological targets, Theralase®’s research strongly (my italics) suggests that Rutherrin® may be activated with radiation therapy, which is able to increase the ‘tumour’s damage zone’ and the effectiveness of Theralase®’s Anti-Cancer Therapy (“ACT”) beyond the reach of light in the body.’
This suggests that if two light activations are to be involved the PDT would be the adjuvant.
‘Once Rutherrin®’s Maximum Tolerated Dose (“MTD”) and hence Human Equivalent Dose (“HED”) limits have been determined through non-Good Laboratory Practices (“GLP”) and GLP toxicology studies, Theralase® plans to inject Rutherrin® systemically into patients via a Phase Ib clinical study, planned for 2022, to allow localization to various cancer cells, including GlioBlastoma Multiforme (“GBM”) and Non-Small Cell Lung Cancer (“NSCLC”) and then activate Rutherrin® with radiation to safely and effectively, destroy the cancer of interest.
Rutherrin®, if proven successful (my italics), would thus be able to “hunt” cancer cells and when activated by radiation “destroy” them; wherever, they may reside in the body.’
So they explicitly state that the success of Rutherrin will be conditional on a systemic immune response though that doesn’t mean that it won’t match or exceed current standard of care without one. Would they be defining - as they are - the success or failure of Rutherrin by reference to the presence or absence of a consequent immune response without good pre-clinical evidence?
Mentioned previous the 270-day results (i.e. 3 months` after second treatment) due with the next quarterly. If TLD-1433 alone was to induce systemic immune responses it would bode well for the more effective and pervasive Rutherrin.